The hereditary angioedema (HAE) treatment market focuses on therapies designed to manage and prevent attacks of hereditary angioedema, a rare genetic disorder characterized by recurrent swelling in various parts of the body, including the skin, gastrointestinal tract, and airways. Treatments include C1 esterase inhibitor (C1-INH) therapies, kallikrein inhibitors, bradykinin B2 receptor antagonists, and novel biologics aimed at reducing the frequency and severity of HAE attacks. Market growth is driven by increasing disease awareness, improved diagnostic rates, and advancements in targeted therapies offering better efficacy and safety profiles. The introduction of subcutaneous and oral therapies has significantly enhanced patient convenience and adherence. Ongoing R&D efforts are also focusing on gene therapies and long-acting biologics to provide sustained disease control.
According to Fortune Business Insights, the global hereditary angioedema treatment market size was valued at USD 5.59 billion in 2024 and is projected to grow from USD 6.53 billion in 2025 to USD 19.68 billion by 2032, exhibiting a CAGR of 17.1% during the forecast period (2025–2032). North America dominated the market with a share of 93.05% in 2024.
Leading companies are focusing on expanding their product portfolios, improving accessibility, and developing cost-effective therapies. CSL Behring, Shire, and Pharming Group NV hold a strong presence in the market through well-established brands and global distribution networks.